Puma Biotechnology | PBYI - Operating Expenses


Puma Biotechnology reported $49.26M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Exelixis USD 359.47M 3.28M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Moderna USD 1.78B 242M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Takeda JPY 1.11T 85.29B Mar/2026
TG Therapeutics USD 170.12M 28.04M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026